HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Encapsulation of anticancer drug copper bis(8-hydroxyquinoline) in hydroxyapatite for pH-sensitive targeted delivery and slow release.

Abstract
There is a conspicuous progress in increasing anticancer drug delivery through the utilization of nanoparticles (NPs) as drug delivery agents. Hydroxyapatite (HA) gives improved clinical effectiveness of drugs by reducing systemic toxicity and broadening the spectrum of drug delivery since it is biocompatible and it can be targeted towards tumor cells. Herein, investigation of the potential of enhancing controlled drug release of the template model drug, copper bis-(8-hydroxyquinoline), by encapsulating it in hollow hydroxyapatite nano-carriers, is presented. Hydroxyapatite nanoparticles are synthesized by following four different routes to optimize its efficacy of drug loading. Copper bis-(8-hydroxyquinoline) is encapsulated by Method (a) which was effected by stirring the model drug and porous HA NPs in colloidal solution and Method (b) which was done during synthesis of hydroxyapatite nanoparticles in a solution of the model drug. In synthesizing nanoporous HA NPs, calcium carbonate is used as a template to create voids in HA. In each method, Ca/P ratio was ensured to be kept at 1.67:1. Appealing results are reported for the encapsulated product which was prepared by Method (a2). Method (a) was done at three different molar ratios of PO43-:CO32- and best result was obtained for that utilized 2.003:1 molar ratio (Method (a2).). It produced 98.67% of encapsulation efficiency and 2.9522mg/g of drug loading capacity. Release kinetics was studied at a range of pH values; the lower the pH of the medium the higher is the drug release. For instance, when considering the product which exhibited high encapsulation efficiency and high drug loading capacity, at pH3.5 during the first 8h it elicited about 13% of release, at pH5.0 about 8% release while at pH6.0 it was just 2.5%. During the 24-hour span, pH3.5 exhibited about 23.8%, at pH5.0 approximately 9% with an increasing trend of release and at pH6.0 showed a value just above 2.5%. As such, acidity of the cancerous cells can be made use to increase the drug slow-release kinetics at the vicinity of the cancer cells.
AuthorsD R K Weerasuriya, W P S L Wijesinghe, R M G Rajapakse
JournalMaterials science & engineering. C, Materials for biological applications (Mater Sci Eng C Mater Biol Appl) Vol. 71 Pg. 206-213 (Feb 01 2017) ISSN: 1873-0191 [Electronic] Netherlands
PMID27987700 (Publication Type: Journal Article)
CopyrightCopyright © 2016 Elsevier B.V. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Delayed-Action Preparations
  • Hydroxyquinolines
  • Organometallic Compounds
  • Durapatite
Topics
  • Animals
  • Antineoplastic Agents (chemistry, pharmacokinetics, pharmacology)
  • Delayed-Action Preparations (chemistry, pharmacokinetics, pharmacology)
  • Durapatite (chemistry, pharmacokinetics, pharmacology)
  • Humans
  • Hydroxyquinolines (chemistry, pharmacokinetics, pharmacology)
  • Organometallic Compounds (chemistry, pharmacokinetics, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: